• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Exopharm

Exopharm

  • Home
  • Products
  • Partnering
  • Science
  • Resources
    • ASX Announcements
    • Investor Information
    • News & Articles
  • About Us
    • Our Values
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
  • Contact

News & Articles

  • All
  • EVs 101
  • News
  • Opinion Articles
  • Papers
  • Talks & Webinars
  • The Life of Science
  • Whitepapers

July 11, 2022 By Exopharm Ltd

Exoria helps illuminate the importance of exercise with age.

Scientists at Exopharm have collaborated with Associate Professor Jason Howitt and his research team at Swinburne University of Technology to probe the molecular processes that occur with aging. NAD+ (nicotinamide adenine dinucleotide), an essential metabolite for energy metabolism, declines with age, however extracellular vesicles (EVs) released by the body during exercise can boost NAD+ levels […]

Filed Under: News, Papers

June 23, 2022 By Exopharm Ltd

Expert View: Extracellular Vesicle Engineering: Optimising Nature’s Non-Immunogenic, Drug Delivery Platform

We are pleased to announce that our Expert View article titled “Extracellular Vesicle Engineering: Optimising Nature’s Non-Immunogenic, Drug Delivery Platform” has been published in ONdrugDelivery. You can check out this Expert View article from Exopharm’s Research and Innovation Manager, Dr Anna Cifuentes-Rius  here . Dr Cifuentes-Rius discusses how to take advantage of EV’s capacity to […]

Filed Under: News, Papers

May 26, 2022 By Exopharm Ltd

Exopharm a LEAP ahead of competitors in emerging exosome medicine field

With a rapidly growing global interest in the superpower of exosomes, major pharmaceutical deals and foundational patents, Exopharm is poised to become an essential part of the modern medicine ecosystem.   As the only listed exosome company on the ASX, and one of a small number of exosome companies listed globally, Australian biopharma Exopharm (ASX:EX1) […]

Filed Under: News

February 1, 2022 By Exopharm Ltd

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

  Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company Initial services are designed to seek to validate Exopharm’s LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm’s facilities in Melbourne followed by the Astellas facilities in Massachusetts USA Future […]

Filed Under: News

December 22, 2021 By Exopharm Ltd

Exopharm Gains US Patent Enabling Commercial Production of Exosome Medicines

  US Patent and Trademark Office has granted Exopharm patent US 11202805, for its LEAP™ exosome purification technology. LEAP™ enables large-scale, clinical grade commercial production of exosomes needed to underpin the emerging field of exosome medicines. Exopharm is seeking potential partners and licensees, with LEAP™ having the potential to become the industry standard for exosome […]

Filed Under: News

October 28, 2021 By Exopharm Ltd

Exopharm shares soar 12% on Q1 update as LEAP tech promises to advance wide range of medicines

Stockhead Article Exopharm has focused on R&D along with key appointments during the start of the new financial year to support its ambitious goal of becoming a leading global exosome medicine company. Shares in exosome medicine company Exopharm (ASX: EX1) peaked almost 12% today after a positive Q1FY22 trading update, with the company making significant advances in […]

Filed Under: News

October 4, 2021 By Exopharm Ltd

Exopharm Strengthens Executive Leadership Team

Mr David Oxley appointed as President – International Dr Johannes K Mühl appointed as Senior Vice President – Finance 4 October 2021, Melbourne, Australia: Exosome medicines company, Exopharm Limited (ASX: EX1) has made two senior appointments in support of its international strategy. Mr David Oxley appointed as President – International David Oxley’s appointment extends the company’s reach […]

Filed Under: News

September 27, 2021 By Exopharm Ltd

Exopharm’s LEAP Technology – Further Step Towards US Patent

Exopharm is a step closer to being granted a US patent for the LEAP technology. The USPTO has issued a ‘Notice of Allowance Mailed’ note for the LEAP patent application (Application 17/147,033). At this point, a USPTO patent number has not been issued in relation to the Application and there are some formalities that need […]

Filed Under: News

September 27, 2021 By Exopharm Ltd

LEAP Article Nomination for BPI Readers’ Choice Award – Downstream Processing

Our peer-reviewed LEAP paper published in BioProcess International is one of 4 nominees for the 2021 BPI Readers’ Choice Awards and is amongst the top 4 popular articles for downstream processing. The paper validates the Ligand-based Exosome Affinity Purification (LEAP) technology as a proprietary answer to the downstream processing bottleneck of exosome purification. Click here to have […]

Filed Under: News, Papers

September 9, 2021 By Exopharm Ltd

Exopharm signs deal with Japanese chemical company as LEAP tech promise to accelerate new cancer-beating research

STOCKHEAD ARTICLE Exopharm will conduct a research collaboration with Japan’s Showa Denko Materials as its LEAP technology shows promise at reducing a major obstacle in the advancement of exosomes as a new form of regenerative medicine for diseases such as cancer. Melbourne Biotech company Exopharm (ASX:EX1) has announced it will undertake a research collaboration with Japan’s Showa […]

Filed Under: News

August 27, 2021 By Exopharm Ltd

Webinar: Overcoming the Delivery Challenge for Nucleic Acid Drugs

On August 26 we presented our Science Webinar with Dr Jennifer King and Dr Anna Cifuentes-Rius about overcoming the delivery challenge for nucleic acid drugs. Deputy CEO & Chief Commercial Officer, Dr Chris Baldwin hosted the event and there was Q&A at the end of the presentations. After the technical and scientific questions were answered, […]

Filed Under: News, Talks & Webinars

July 21, 2021 By Exopharm Ltd

From mesenchymal stromal cells to engineered extracellular vesicles: A new therapeutic paradigm

We are excited to announce the publishing of our review article titled From mesenchymal stromal cells to engineered extracellular vesicles: A new therapeutic paradigm. You can access the paper on the Frontiers in Cell and Developmental Biology journal here. Abstract Mesenchymal stromal cells (MSCs) are multipotent cells obtained from many tissues including bone marrow, adipose […]

Filed Under: News, Papers

July 14, 2021 By Exopharm Ltd

Shareholder Update Webinar – July 2021

Here is the recording from Exopharm’s shareholder update webinar held on 13 July 2021. Founder & CEO, Dr Ian Dixon, provided an update on RNA delivery using exosomes and developments relating to Exopharm’s LEAP technology IP. Following this, CCO/Deputy CEO, Dr Chris Baldwin discussed ongoing commercial activity relating to the Company. The webinar was hosted […]

Filed Under: News, Talks & Webinars

June 30, 2021 By Exopharm Ltd

Investor Presentation: Stockhead V-Con

Here is our latest investor presentation from Stockhead’s V-Con. This video conference focuses on the Australian biotech sector, medical innovations and breakthrough treatments. Deputy CEO & Chief Commercial Officer, Dr Chris Baldwin provides updates on the exosome technology and exosome medicines programs at Exopharm.

Filed Under: News, Talks & Webinars

June 19, 2021 By Exopharm Ltd

Exopharm’s first LEAP Paper has been published

We are pleased to announce that our first LEAP Paper has been published. In our studies, ligand-based exosome affinity purification (LEAP) technology has proven to be an efficient, robust, scalable, low-cost, and highly reproducible EV purification platform technology. The patented technology is suited to the manufacture of naive EV and engineered EV products. When compared […]

Filed Under: News, Papers

June 16, 2021 By Exopharm Ltd

The Life of Science – Chantelle

Our next video in our ‘Life of Science’ series stars Chantelle Blyth – our Research Scientist from the Upstream Processing Team. One of the key aspects of Chantelle’s role is upscaling our cell culture process from millilitres to litres. Inquisitive and vibrant, she tackles challenges with a creative edge to get tangible end results. Chantelle is passionate […]

Filed Under: News, The Life of Science

May 31, 2021 By Exopharm Ltd

Edison Group Initiates Coverage on Exopharm

Investment research, investor relations and consulting firm Edison Group initiates research on Exopharm.

Filed Under: News

April 21, 2021 By Exopharm Ltd

$12m capital raising puts Exopharm in strong position to negotiate new partnerships

“The proceeds from the capital raise together with the 2021 R&D rebate later in the year will put the company in a strong financial position to realise its strategy of becoming a world leader in exosome medicines through the commercialisation of its technology platforms and the development of new exosome medicine,” says Chief Executive Officer […]

Filed Under: News

April 13, 2021 By Exopharm Ltd

Pitt Street Research says Exopharm worth up to $4.71 a share

“With its foundation LEAP technology, Exopharm has arguably the world’s best tools for manufacturing exosomes,” Pitt Street analysts Stuart Roberts and Cheng Ge wrote. We are proud to be at the forefront of the emerging exosome medicines field and for the many opportunities ahead. Click here for the full Stockhead article.    

Filed Under: News

April 13, 2021 By Exopharm Ltd

Pitt Street Research initiates coverage on Exopharm

Pitt Street Research has published a 29-page report on Exopharm. Base case valuation of $2.80 per share ($0.66 today), driven by the company’s LEAP technology.   Access the full Pitt Street Report here. To go to the Pitt Street Research page, click here.      

Filed Under: News

April 12, 2021 By Exopharm Ltd

Q&A with StockPal

Watch Dr Chris Baldwin, Deputy CEO & COO, as he explains Exopharm’s latest developments and potential target markets. 0:00​ – Intro 0:10​ – What is your business about? 1:20​ – Tell us about your product developments and pipeline? 3:01​ – What is the size of your potential target markets? 4:16​ – What is EX1’s competitive advantage? 5:30​ – How did your […]

Filed Under: News, Talks & Webinars

April 8, 2021 By Exopharm Ltd

Exopharm’s great LEAP forward gets an all-clear cheers from Finland’s Red Cross service

“Dr Laitinen and her team are the perfect first partners for manufacturing Plexaris and other blood EV products for Europe. We are equally excited to be preparing to transfer the LEAP technology to FRCBS so they can produce blood cell derived EV medicines,” said Dr Chris Baldwin, Chief Commercial Officer. “For Exopharm, this is the first […]

Filed Under: News

April 6, 2021 By Exopharm Ltd

Shareholder Update – April 2021

In this webinar, Dr Ian Dixon, Exopharm’s Managing Director and Founder, discusses three recent ASX announcements and answers questions in a Q&A facilitated by Paul Hart, Executive Director of Canary Capital. The following ASX announcements are addressed: 01/04/2021  Preclinical Data from Osteoarthritis Animal Study 06/04/2021  Positive PLEXOVAL II Phase 1 Clinical Trial Results 06/04/2021  LEAP Technology- Advanced EV […]

Filed Under: News, Talks & Webinars

March 19, 2021 By Exopharm Ltd

Shareholder Presentation – Twilight Investor Briefing March 2021

We presented at the Twilight Investor Briefing on March 11 hosted by FB Rice and organised by Monsoon Communications.  We would like to thank the organisers for the opportunity to share our exosome medicine strategy, unique technology platform and show why this is the Year We LEAP as we work to empower exosome medicine discovery […]

Filed Under: News, Talks & Webinars

March 8, 2021 By Exopharm Ltd

7NEWS | Melbourne researcher working on COVID treatment suitable for those with health conditions

“I was more driven last year than ever before to really find that anti-viral to get it into the clinic”, said Dr. Ranja Salvamoser, Head of Experimental Biology. In light of International Women’s Day today, and every other day, we celebrate the work and achievements of the incredible women in our company. Ranja is leading her […]

Filed Under: News

March 5, 2021 By Exopharm Ltd

The Life of Science – Aislinn

With International Women’s Day around the corner, we share with you our third profile video featuring Aislinn Treloar, our multi-talented Business Development Manager. As an inspiring and humble leader, Aislinn has played a pivotal role in advancing our technologies through collaborations and partnerships and is one of the many amazing women who work at Exopharm.  

Filed Under: The Life of Science

February 25, 2021 By Exopharm Ltd

Exopharm preps for great LEAP forward as world catches onto exosome promise

“People have begun to understand that our destiny is not only in our hands, it is in the hands of the entire exosome research community, and everybody who is trying to develop exosome medicines, because there’s no technology that has been demonstrated that can produce thousands, much less tens of thousands or hundreds of thousands […]

Filed Under: News

February 19, 2021 By Exopharm Ltd

Early Careers in Science Webinar

Early Careers in Science Webinar – Hosted by Exopharm 18 February 2021 12-12.45pm AEDT Choosing a career path can be daunting, and we understand this.  Aimed at high school students, this free webinar provided some insight into a career in science and featured speakers from Exopharm who are passionate about helping students embrace this field. […]

Filed Under: News, Talks & Webinars

February 16, 2021 By Exopharm Ltd

Exopharm presents at BIO CEO & Investor Digital Conference

We presented at the BIO CEO & Investor Digital Conference which is taking place from 16-18 February. Our Chief Commercial Officer, Dr. Chris Baldwin, provided insight into our company,  exosomes in general and the technologies we are using to bring exosome therapeutics to the world. You can find the slide deck here.

Filed Under: News, Talks & Webinars

February 4, 2021 By Exopharm Ltd

The Life of Science – Sam

Today we share with you the second profile video in our series called “The Life of Science”. This video features Sam Law, our Process Engineer. Sam drives the execution of all things related to exosome isolation and manufacturing. He is a true team player and a tinkerer by nature.  

Filed Under: News, The Life of Science

February 2, 2021 By Exopharm Ltd

Edison Open House – Global Healthcare 2021 Interview

Watch our interview at the Edison Group Open House: Global Healthcare 2021 Conference.

Filed Under: News, Talks & Webinars

January 28, 2021 By Dr. Ian Dixon

Value in new medicines and ‘longer strides’

“There are more than 150 listed biotech companies on the ASX, so you need to back a select shortlist to outperform. While the science is often complex, look for companies that are capable of taking longer strides over the medium term,” says Dr. Ian Dixon, Managing Director & Founder. You can access the full Stockhead article […]

Filed Under: News, Opinion Articles

November 18, 2020 By Exopharm Ltd

Presentation recording – Exosome TX Summit

Producing EVs at the Clinical Scale On November 11, we presented at the Exosome Based Therapeutic Development Digital Summit. At this key exosome industry event, we had the opportunity to highlight our LEAP technology, the team’s accomplishments and our commitment to collaboration to advance the development of all exosome therapeutics. Our Chief Commercial Officer, Dr […]

Filed Under: News, Talks & Webinars

November 13, 2020 By Exopharm Ltd

Exopharm’s LEAP technology a breakthrough in exosome therapeutics

“The biggest problem is to purify the EVs from their source and to eliminate the contaminants, and not damage the EVs,” says Managing Director and founder Dr Ian Dixon. One of the great things about our LEAP technology and process is that it is scalable. You can read the full Stockhead article here.

Filed Under: News

November 11, 2020 By Exopharm Ltd

Exopharm to Present at Key Exosome Industry Event

Chief Commercial Officer, Dr Chris Baldwin, will present to the Exosome Based Therapeutic Development Digital Summit on 11 November (9:00 AM US Eastern Time, 1.00 AM AEDT), the first day of the two-day event. You can find the slide deck here.  

Filed Under: News

November 6, 2020 By Exopharm Ltd

Webinar Nov 2020 – Behind the scenes with our scientists

Our science is too important to leave to just the scientists. On November 5, Dr Balarka Banerjee and Dr Kartini Asari explained some of the advances Exopharm is making. This science update forms part of our ‘Behind the Scenes’ webinar series.   Stem Cells: Exosome Factories Dr. Balarka Banerjee, Cell Development Manager Exopharm’s unique LEAP […]

Filed Under: News, Talks & Webinars

October 23, 2020 By Exopharm Ltd

Exopharm has just dosed its first patient in a wound-healing study

“With a successful outcome from PLEXOVAL II, Exopharm will be well-positioned to initiate Phase 2 studies with off-the-shelf Plexaris and Phase 1 studies with our mesenchymal stem cell EV product Cevaris,” said Angus Tester, Head of Product Evaluation. You can read the full Stockhead article here.   

Filed Under: News

October 15, 2020 By Exopharm Ltd

Health Kick Podcast: This biopharma company may be the world’s only exosome-based player

Yesterday, Chief Commercial Officer Chris Baldwin sat down with Stockhead’s resident health and biotech expert Tim Boreham for the latest episode of The Health Kick Podcast. They discuss the potential of exosomes to transform healthcare, and our journey to commercialising our exosome therapeutics. Click below to listen. You can find the full post here. 

Filed Under: News, Talks & Webinars

October 7, 2020 By Exopharm Ltd

How mRNA vaccines could defeat the novel coronavirus

How mRNA vaccines could defeat the novel coronavirus   Head of Innovation Andy Coley spoke with Stockhead about the potential of mRNA for fighting COVID-19, including Moderna’s vaccine candidate and Fortrexo, our engineered EV approach. You can find the full article here.  

Filed Under: News

September 24, 2020 By Exopharm Ltd

ShareCafe – Hidden Gems Webinar

ShareCafe’s “Hidden Gems” Webinar 18 Sept 2020 Chief Commercial Officer Chris Baldwin provides updates on Exopharm’s Technology and Naive EV programs, including the addition of Alison Mew to the senior leadership and the progress on Exopharm’s second clinical trial.  

Filed Under: News, Talks & Webinars

September 3, 2020 By Exopharm Ltd

Webinar Sept 2020 – Science Update

Behind the Scenes with our Scientists Recently, there has been a variety of updates about the company’s business progress and accomplishments. This webinar provided a closer look at some of science and technology behind our most recent advances, Fortrexo CoV™ and Exoria™.   RNAi’s to Stop Coronavirus Dr Karen Holden, Head of Translation Exopharm has […]

Filed Under: News, Talks & Webinars

September 1, 2020 By Exopharm Ltd

Exopharm Raises $10 million

Exopharm has announced a placement of shares to raise $10 million. Canary Capital, the manager of the placement, and its directors have elected to take the majority of their fees in shares. “In Exopharm, Canary has identified an Australian company with proprietary technology that can compete on the world stage”, says Paul Hart, Executive Director […]

Filed Under: News

August 20, 2020 By Exopharm Ltd

Exopharm’s Big Idea Heading For A Big Business In EV Medicines

“As a serial biotechnology entrepreneur, Dr Dixon doesn’t just develop technologies or products – he wants to build long-lasting businesses based upon big ideas.” Written by our Chief Commercial Officer Chris Baldwin, this Sharecafe article explains Dr Dixon’s big idea back in 2013 and how it led to the foundation of Exopharm. Today, Exopharm is […]

Filed Under: News

August 11, 2020 By Exopharm Ltd

Webinar July 2020 – Shareholder Update

Exopharm CCO Dr Chris Baldwin gives a shareholder update on the ‘Morning Twilight Briefing’ webinar series hosted by Monsoon Communications. Chris discusses Exopharm’s key development areas and provides an overview of the company’s engineered EV technology.  

Filed Under: News, Talks & Webinars

August 11, 2020 By Exopharm Ltd

A Quest Grounded in Commercial Basics

Biotech Daily’s Tim Boreham likes Exopharm’s focus: “Given the scientifically complex nature of Exopharm’s quest to develop exosomes into therapeutics, it’s good to see that founder and chief executive Ian Dixon hasn’t lost sight of the commercial basics.” Read the full article here.  

Filed Under: News

July 27, 2020 By Exopharm Ltd

MST Access Initiates Coverage of Exopharm

MST Access, a division of MST Financial which provides institutional-grade research for small and medium cap companies, has initiated coverage of Exopharm Ltd (ASX: EX1). Read the full report here.

Filed Under: News

June 9, 2020 By Exopharm Ltd

Their Curiosity and Enthusiasm are Infectious

Their Curiosity and Enthusiasm are Infectious… Recently Chief Commercial Officer Chris Baldwin sat down with StockPal to discuss the CEO mindset. Read Chris’ thoughts on Exopharm, measuring success, and the future of exosome medicines. Read the full article on Stockpal Asia.  

Filed Under: News

The Exopharm BD Team

June 5, 2020 By Exopharm Ltd

BD Team Welcomes Partners

BD Team Welcomes Partners The Business Development team is excited to be participating in the virtual “Bio Digital Partnering Convention 2020.”  With over 30 meetings with potential business partners from around the globe already planned, they are eager to find partners to help us in our mission to bring exosome medicines to the world. Other […]

Filed Under: News

June 1, 2020 By Exopharm Ltd

Exopharm Webinar May 2020 – Our Strategic Response to COVID-19

Exopharm Webinar May 2020 – Our Strategic Response to COVID-19 Exopharm updates the public on its recent progress and activities. Hosted by Jason Watson, Chair of Exopharm, Ian Dixon (CEO), Gregor Lichtfuss (COO) and Chris Baldwin (CCO) discuss how COVID-19 has affected operations and strategies. The application of Exopharm’s engineered exosome program, Fortrexo, is discussed, […]

Filed Under: News, Talks & Webinars

May 25, 2020 By Dr. Ian Dixon

Exosomes as Next-Generation Cell-free Medicines

Dr. Ian Dixon: Bio Insights Exosomes at scale as next-generation cell free medicines: Fact and Fiction In 2020, exosomes (also known as extracellular vesicles [EVs]) are emerging from academic laboratories and into biotechnology company led clinical trials. But this progress has, until now, been held back by the absence of a robust, scalable and proprietary […]

Filed Under: EVs 101, Opinion Articles, Whitepapers

April 13, 2020 By Dr. Ian Dixon

Seeing Exosomes’ Potential To Treat Sensory Disability

  Early studies suggest regenerative medicine could halt or even reverse the onset of age-related sensory impairment Gradually losing the ability to experience and enjoy the world around you can be one of the most debilitating aspects of ageing. Vision impairment, hearing loss and other sensory disabilities affecting smell, taste or touch are among the […]

Filed Under: EVs 101, Opinion Articles

January 31, 2020 By Dr. Ian Dixon

Exosomes: Nanoparticles full of Surprises

Exosomes: Nanoparticles full of Surprises If the past few years of exosome research has taught us anything about these tiny biomolecule-filled parcels, it is that ‘what do exosomes do?’ is the wrong question to ask. In the context of cell to cell communication, ‘what don’t exosomes do’ seems to be a better starting point. As […]

Filed Under: EVs 101, Opinion Articles

January 7, 2020 By Dr. Ian Dixon

Destination: Exosomes

Destination: Exosomes A growing number of stem cell companies are seeing the light and shifting their focus to exosome products. An interesting mixture of companies are lining up to follow Exopharm’s lead and begin human clinical trials of therapeutic exosome candidates. At least three exosome companies are aiming to start clinical trials during 2020, and […]

Filed Under: Opinion Articles

Exosomes as Drug Delivery Vehicles

December 17, 2019 By Dr. Ian Dixon

Exopharm backs regulatory crackdown on unapproved exosome products

Exopharm backs regulatory crackdown on unapproved exosome products A leading developer of exosome therapies, Australia-based Exopharm Limited, supports the US Food & Drug Administration (FDA) in highlighting the health dangers of unapproved products peddled by clinics that are openly flouting the rules. In a public safety notification released on December 6, the FDA highlighted reports […]

Filed Under: News

December 9, 2019 By Dr. Ian Dixon

What Are Exosomes and Why Are Exosomes Important?

What Are Exosomes and Why Are Exosomes Important? What Are Exosomes? Definition of Exosomes Exosomes are defined as nanometre-sized vesicles, being packages of biomolecules ranging from 40-150 nanometres in size that are released by virtually every cell type in the body. Once thought to be a kind of refuse disposal system for cells, exosomes are […]

Filed Under: EVs 101, Opinion Articles

December 5, 2019 By Dr. Ian Dixon

The New Science of Aging: Winding Back the Body Clock

The New Science of Aging: Winding Back the Body Clock Human age reversal has jumped from pure science fiction to research reality. Until very recently, the idea of age reversal and rejuvenation in humans was not a topic discussed in serious scientific circles. The idea was, at best, highly speculative. At worst it was the […]

Filed Under: Opinion Articles

Ageing and exosomes in regenerative medicine

October 30, 2019 By Dr. Ian Dixon

Turning Back the Body Clock With Exosomes

Turning Back the Body Clock With Exosomes New research reinforces the possibility that exosomes derived from stem cells can bring the body back into a more healthful, youthful state. Two recent publications highlight the growing relevance of exosomes to aging. One report highlights that the aging of humans is associated with an accelerating decline in […]

Filed Under: EVs 101, Opinion Articles

October 10, 2019 By Dr. Ian Dixon

Exosomes: Tiny Particles with Big Potential

The Potential of Exosomes Exosomes are moving toward clinical use in numerous and diverse ways There are around 37 trillion cells in a human body—and like any collective of diverse individuals they rely upon constant communication to work together. Just over a decade ago a research team in Sweden published in Nature Cell Biology a […]

Filed Under: EVs 101

regenerative medicine and exosome research

September 17, 2019 By Dr. Ian Dixon

The Power of Exosome Therapy in Regenerative Medicine

Understanding regenerative medicine’s point-of-difference Companies testing exosome-based therapies are developing completely new ways to tackle the wide array of medical conditions that afflict us in old age. Exosomes from stem cells are an emerging regenerative medicine that could disrupt the way age-related degeneration is treated, including problems such as cardiovascular disease, neurodegeneration, osteoporosis and erectile […]

Filed Under: EVs 101, Opinion Articles

Exopharm Sport

September 4, 2019 By Exopharm Ltd

Understanding and Sharing our Progress at Exopharm

Exopharm: Preparation, Demonstration and Reward As a biotech stock, order or to maximise the financial returns from our technologies and products there are a number of aspects to the business of Exopharm. As a headline, we see ourselves as world leaders in a new type of regenerative medicine – harnessing exosomes as the ‘secret sauce’ […]

Filed Under: Opinion Articles

Exosomes Therapeutics

August 6, 2019 By Dr. Ian Dixon

Exosomes and Therapeutic Research

Exosome Therapeutic Research Emerging from the Lab The more we study these naturally produced packets of biomolecules, the more therapeutic use they seem to lend themselves to be. Exosomes, pro-healing nanoparticles found naturally in the body, are a new potential paradigm in healthcare that could assist in every step we take through life. In their […]

Filed Under: EVs 101

Exosomes vs Stem Cell Therapys

July 17, 2019 By Dr. Ian Dixon

The Next Big Thing: Exosomes versus Stem Cells

Exosomes vs Stem Cells: Exosomes as the Next Big Thing after Stem Cell Therapy The exosomes (or ‘extracellular vesicles’) released by stem cells may be the disruptive therapy for tackling age-related diseases doctors and patients have been waiting for. Despite over a decade and a half of hope and hype, stem cell therapy has failed […]

Filed Under: News

Exopharm Reducing Risk - Making Drugs by Purifying not Synthesising

July 4, 2019 By Dr. Ian Dixon

Exopharm: Reducing Risk. Making Drugs by Purifying not Synthesising

Exopharm: Reducing Risk. Making Drugs by Purifying not Synthesising In this note to shareholders and potential investors, the company outlines Exopharm’s risk-profile and how the business of Exopharm compares with other types of listed biotechnology companies. Exopharm: Context Exopharm is an ASX listed regenerative medicine company focused on bringing exosomes into clinical use as a […]

Filed Under: News

What are Exosomes

June 11, 2019 By Dr. Ian Dixon

What are Exosomes and How Exosomes Work as a Regenerative Medicine

Exosomes (or extra cellular vesicles) are a new way to treat medical conditions including health span related medical problems. Exosomes are showing a great deal of promise in the Biotech industry as the future of regenerative medicine. What Are Exosomes? Exosomes are tiny packages of biomolecules released by cells1. They range between 40 and 200 […]

Filed Under: News

Anticipation in the Exosome Field

May 27, 2019 By Dr. Ian Dixon

Investors Show Growing Enthusiasm in Exosome Biotech Stocks

Biotech and Exosome Investment Growth Recent financial transactions highlight increasing biotech investment activity in the field of exosomes and extracellular vesicles. These naturally occurring packets of biomolecules could represent a new paradigm in healthcare. Exopharm Limited (ASX-EX1) is one of a small number of Australian biotech stocks currently attracting investors in regenerative medicine, and its […]

Filed Under: News

The power of Exopharm’s LEAP technology

March 27, 2019 By Dr. Ian Dixon

The Power of Exopharm’s LEAP Technology

The Critical Bottleneck of Exosome Isolation and the Power of Exopharm’s LEAP Technology Why Exopharm is poised to be a leader in the field of therapeutic exosomes. Exosomes (also known as extracellular vesicles or EVs) from stem cells are poised to become a new form of regenerative medicine – described by some as the ‘secret […]

Filed Under: News

What is Regenerative Medicine

January 31, 2019 By Dr. Ian Dixon

Australian Regenerative Medicine: Questions and Answers

Regenerative Medicine: Questions and Answers What is regenerative medicine? Regenerative medicine is a term used to cover different ways scientists can harness the body’s own regenerative capabilities. What are some examples of regenerative medicines? An old example is blood. Blood (or blood plasma) from donors is used routinely in hospitals if the patient needs more […]

Filed Under: News

Exosome introduction Notes

January 1, 2018 By Dr. Ian Dixon

Meet the Exosomes

Meet the Exosomes Exactly a decade ago, a seminal paper revealed the role exosomes play in the body. Read on for Exopharm’s guide on what exosomes are, and why they’re beginning to create a buzz in medical circles. Human cells are a gregarious bunch – otherwise we would fall apart. They continually message each other, […]

Filed Under: News

Exosomes Linking Obesity and Diabetes

January 1, 2018 By David Parker

Exosomes Linking Obesity and Diabetes

Exosomes Linking Obesity and Diabetes Exosomes from lean individuals can reverse the symptoms of diabetes associated with obesity, a new animal study shows Inflammatory exosomes are the missing link by which obesity causes type 2 diabetes, researchers from the University of California San Diego have shown. The discovery could lead to earlier diabetes diagnosis and […]

Filed Under: News

Exosome research

July 1, 2017 By Dr. Ian Dixon

Clearing the Hurdles with Exosomes

Could exosome therapy help athletes recover from injury faster – and help the rest of us by mimicking the whole-body benefits of exercise? Some people don’t get enough physical exercise – but others suffer from too much activity, injury and over-training. Many sports players are set to benefit from the dawning era of exosome medicine. […]

Filed Under: News

Exosomes as Drug Delivery Vehicles

January 1, 2017 By Dr. Ian Dixon

Exosomes as Drug Delivery Vehicles

Exosomes as Drug Delivery Vehicles: Natural Nano-bio-drones In the not too distant future, click ‘buy’ on an internet shopping site and an autonomous drone will be dispatched to carry your new goods directly to your doorstop. For now, drone home-delivery is still science fiction – but inside the body, targeted autonomous delivery of packages is […]

Filed Under: News

Footer

Resources

  • ASX Announcements
  • Investor Information
  • Board of Directors
  • News & Articles

Information

  • Contact
  • Partnering
  • Join Our Mailing List
  • Privacy, Terms and Conditions
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Copyright © 2022 · Exopharm · ACN 163 765 991 · info@exopharm.com
Level 17/31 Queen St, Melbourne VIC Australia 3000 · P: +61 (0)3 9111 0026 ·

Web Design by Mallee Blue Media
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT